Overview

This trial is enrolling by invitation only.

Condition healthy
Treatments dichloroacetate (dca), gstz1 haplotyping
Sponsor University of Florida
Collaborator Medosome Biotec LLC
Start date March 2016
End date February 2017
Trial size 50 participants
Trial identifier NCT02690285, IRB201500995

Summary

The purpose of this study is to identify and analyze the frequency of GSTZ1 haplotypes in a healthy adult population and determine the pharmacokinetics of Dichloroacetate (DCA) metabolism based on haplotype analysis.

The DCA drug is the first targeted treatment for Pyruvate Dehydrogenase Complex Deficiency (PDCD).

This pilot study, focuses on developing a high throughput, sensitive and accurate screening test for determining glutathione transferase zeta 1 (GSTZ1) haplotype status in individuals who would be treated with DCA.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation non-randomized
Endpoint classification pharmacokinetics study
Intervention model single group assignment
Masking open label
Primary purpose screening
Arm
(Other)
The participants will have blood collection and cheek cell collection after signing the informed consent, to determine GSTZ1 haplotype.
gstz1 haplotyping Blood collection
One teaspoon of blood is collected by standard phlebotomy. Cheek cells are collected by standard brushing. Samples will be analyzed at two independent laboratories to validate methods for GSTZ1 haplotype analysis.
(Experimental)
Ten study participants will be administered oral Dichloroacetate (DCA) 25 mg/kg daily for 5 days. On the fifth day frequent blood samples will be obtain over the following 24 hours. Study participants will remain at the Clinical Research Clinic (CRC) for the duration of the DCA kinetic study on day 5.
dichloroacetate (dca)
Dichloroacetate (DCA) 25 mg/kg oral solution will be administered daily for 5 days.
gstz1 haplotyping Blood collection
One teaspoon of blood is collected by standard phlebotomy. Cheek cells are collected by standard brushing. Samples will be analyzed at two independent laboratories to validate methods for GSTZ1 haplotype analysis.

Primary Outcomes

Measure
GSTZ1 haplotype frequency
time frame: Baseline Visit

Secondary Outcomes

Measure
Peak Plasma Concentration (Cmax) of Dichloroacetate (DCA)
time frame: -10, 0, 5, 10, 20, 30 minutes and at 1, 2, 4, 6, 8, 12, 24, 30 hours post dose

Eligibility Criteria

Male or female participants from 18 years up to 70 years old.

Inclusion Criteria: - Healthy as outline in the physical exam and blood tests - Non smoker Exclusion Criteria: - Cannot comprehend or refuse to sign the informed consent form; - Febrile or have other clinical signs of infection; - Pregnant or are nursing; - In females, cannot or refuse to use contraception or avoid unprotected intercourse during the study; - Uncontrolled hypertension (BPs > 160 mmHg or BPd > 100 mmHg) on conventional medication; - Anemic (hematocrit < 35% in males; < 35% in females; - Serum creatinine ≥ 1.3 mg/dl, TSH > 4.5 mIU/ml; a transaminase (ALT or AST) > 2 x ULN, total bilirubin > 1.2 mg/dl or fasting glucose ≥ 110 mg/dl. - History of psychosis, seizures or diabetes mellitus or be receiving anti-psychotic, anti-epileptic or blood glucose-lowering medication.

Additional Information

Official title A Pilot Study of Rapid Haplotyping Procedure for Personalized Dosing of Dichloroacetate (DCA) in Healthy Volunteers Part 1: Rapid Haplotyping Procedure for Determining the Response of Patients to DCA. Part 2: Personalized Dosing of Dichloroacetate for the Treatment of Rare and Common Diseases
Principal investigator Peter W Stacpoole, PhD, MD
Description Pyruvate dehydrogenase complex (PDC) deficiency (PDCD) is a rare disease of mitochondrial energy failure with the life of expectancy of affected children severely truncated. Treatment of PDCD remains a serious, unmet challenge. Dichloroacetate (DCA) represents the first targeted therapy for PDCD by stimulating residual PDC activity. Cumulative experience with DCA has revealed dose accumulation in a subset of the population. This can be abated through personalized dosing of DCA, assigned by haplotype variation in the gene encoding glutathione transferase zeta 1 (GSTZ1), which biotransforms DCA to glyoxylate. Haplotype variations in GSTZ1 influence the kinetics and dynamics of chronically administered DCA. A single dose of DCA has a bioavailability approaching unity and is widely distributed throughout the body. The plasma half-life (t ½) is ~1 hr in drug-naïve subjects. Gender does not influence DCA kinetics or metabolism. The major route of biotransformation is via dehalogenation to glyoxylate by glutathione transferase zeta 1 (GSTZ1). DCA is a mechanism-based inhibitor of GSTZ1, so repeated administration results in increased plasma t ½ and decreased clearance.
Trial information was received from ClinicalTrials.gov and was last updated in November 2016.
Information provided to ClinicalTrials.gov by University of Florida.